Canada: Recall, Report, Relabel: Bill C-17 Increases Oversight Of Drugs And Medical Devices

Bill C-17, An Act to Amend the Food and Drugs Act (Bill), received royal assent on November 6, 2014. The Bill applies to medical devices and prescription and over-the-counter drugs (collectively, therapeutic products), but does not apply to natural health products.

The Bill grants the Minister of Health (Minister) substantial new powers, including the power to order recalls, collect post-market safety information, and implement label changes. The Bill also imposes increased penalties for noncompliance and, perhaps most controversially, permits the disclosure of confidential business information relating to therapeutic products without consent or notice under certain circumstances. The Bill is in line with Health Canada's general trend over the last few years towards increased safety regulations, including the Canada Consumer Product Safety Act, which came into force in 2011 and the Safe Food for Canadians Act, which was passed in 2012 but is not yet in force.

The salient features of the Bill are set out below.


Bill C-17 contains numerous provisions that impose additional post-market obligations on manufacturers and/or sellers of therapeutic products. For instance, the Bill allows the Minister to:

  • Order the seller of a therapeutic product to recall the product if the Minister believes the product presents a serious or imminent risk of injury to health
  • Order a manufacturer to modify a therapeutic product's label or to modify or replace its packaging if the Minister believes that doing so is necessary to prevent injury to health
  • Order a manufacturer to conduct certain assessments, tests, or studies in respect of a therapeutic product, and to provide the results to the Minister.

Many Canadians were unaware that prior to this Bill, the Minister did not have the power to recall a therapeutic product although the Minister had the ability to issue unilateral communications regarding the safety of a therapeutic product, suspend a company's product approval and/or issue other orders regarding the sale of an impugned product.

The Bill also enables the Governor in Council to make regulations that would trigger additional obligations, such as regulations requiring manufacturers to disclose clinical trial data to the public in a prescribed time and manner, and to provide safety-related information (e.g. regarding labelling changes that have taken place outside Canada) to the Minister.


The Bill sets out several circumstances under which the Minister may disclose confidential business information (CBI), which may include trade secrets. Specifically, the Bill allows the Minister to disclose or release CBI without notice or consent:

  • To anyone, including the public, if the Minister believes the product may present a serious risk of injury to human health
  • To a government (including foreign government), a government adviser, or a person who carries out functions relating to the protection or promotion of human health or safety of the public, if the purpose of the disclosure is related to the protection or promotion of human health or the safety of the public.

Further, the Bill permits the Governor in Council to make regulations designating certain business information as non-confidential (or specifying circumstances in which CBI ceases to be confidential) and allowing such information to be disclosed without notice or consent.

This new disclosure regime, which is more permissive than regimes in the United States and the European Union, has raised concerns about Canada's compliance with international trade obligations relating to the protection of trade secrets and other confidential data. In response, Minister Rona Ambrose has publicly confirmed her commitment that any disclosure of CBI will only occur in a manner that is consistent with Canada's treaty obligations.


In addition, the Bill allows the Minister to make regulations requiring health-care institutions to report adverse drug reactions or medical device incidents. The switch from voluntary to mandatory reporting would require significant new compliance measures by affected institutions.


Increased penalties for contravention accompany the new obligations under the Bill. For instance, a person who contravenes a provision of the Food and Drugs Act or its regulations relating to a therapeutic product is now liable for a monetary penalty of up to C$5 million per day and/or imprisonment for up to two years. The Bill also sets out additional officer, director and agent liability where such individuals direct, authorize, assent to, acquiesce or participate in an offence committed by a corporation, and such individuals are liable to the same strict penalties set out above.

These tougher penalty provisions are counterbalanced by a new due diligence defence to prosecutions for offences under the legislation. Note, however, that the due diligence defence cannot be evoked where a person has knowingly made false or misleading statements to Health Canada or has knowingly or recklessly caused a serious risk of injury to human health in contravening a provision relating to a therapeutic product. In such cases, the maximum penalties set out above do not apply and harsher punishments may be imposed on a discretionary basis by the court.


Most of the Bill came into force upon royal assent, including the tougher penalties and the Minister's new powers to order recalls, require labelling changes and disclose CBI and new information about a product. However, there are a few provisions that will come into force at a later date and after relevant regulations have been developed, including the power to publicly disclose negative regulatory decisions. Companies should monitor the regulatory landscape closely, as portions of the Bill will be further defined through regulation in the coming months and years.

Given the new obligations imposed under the Bill and the significant consequences of a violation, pharmaceutical and medical devices companies should review their compliance programs carefully to ensure that any applicable post-market requirements can be met. A good compliance program both reduces the likelihood of non-compliance with the Bill and may also be used as evidence of due diligence in the event a violation occurs.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
27 Oct 2016, Seminar, Toronto, Canada

Please join members of the Blakes Commercial Real Estate group as they discuss five key provisions of a commercial real estate purchase agreement that are often the subject of much negotiation but are sometimes misunderstood.

1 Nov 2016, Seminar, Toronto, Canada

What is the emotional culture of your organization?

Every organization and workplace has an emotional culture that can have an impact on everything from employee performance to customer or client satisfaction.

3 Nov 2016, Seminar, Toronto, Canada

Join leading lawyers from the Blakes Pensions, Benefits & Executive Compensation group as they discuss recent updates and legal developments in pension and employee benefits law as well as strategies to identify and minimize common risks.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.